<DOC>
	<DOCNO>NCT00620971</DOCNO>
	<brief_summary>This trial evaluate whether sequential administration Cisplatin/Vinorelbine/Bevacizumab follow Docetaxel/Gemcitabine/Bevacizumab versus Cisplatin/Docetaxel/Bevacizumab combination first line treatment offer survival advantage patient locally advance metastatic NSCLC .</brief_summary>
	<brief_title>Cisplatin/Vinorelbine/Bevacizumab Followed Docetaxel/Gemcitabine/Bevacizumab Versus Cisplatin/Docetaxel/Bevacizumab Combination Locally Advanced Metastatic NSCLC</brief_title>
	<detailed_description>An unanswered question first line treatment non small cell lung cancer ( NSCLC ) whether administration 2 active drug provide great efficacy two-drug combination . Docetaxel/gemcitabine combination well tolerated regimen , comparable efficacy docetaxel/cisplatin vinorelbine/cisplatin . In recent phase II study first line treatment advance metastatic NSCLC , sequential administration vinorelbine/cisplatin follow docetaxel/gemcitabine produce response rate 45.8 % 1-year survival rate 51 % . The addition bevacizumab platinum-based regimen provide survival benefit patient advance metastatic NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm , unresectable locally advanced ( stage IIIB pleural effusion ) metastatic ( stage IV ) nonsquamous NSCLC Performance status ( WHO ) 01 Adequate bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥ 100,000/mm3 , Hgb ≥ 11 g/dL ) , liver ( Bilirubin ≤ 1.5 UNL , SGOT/SGPT ≤ 2.5 UNL , ALP ≤ 5 UNL ) , renal function ( Creatinine ≤ UNL borderline , creatinine clearance ≥ 60 mL/min ) No previous chemotherapy immunotherapy advanced/metastatic NSCLC allow Previous radiotherapy allow provide measurable lesion outside radiation field Measurable disease , define least 1 bidimensionally measurable lesion ≥ 20 X 10 mm Patient able take oral medication Absence active CNS disease Paraffin embed sample primary metastatic tumor diagnostic specimen must available Patients must able understand nature study give write informed consent Pregnant lactate woman Women childbearing age unable unwilling take effective contraceptive measure Active CNS disease , brain metastasis , leptomeningeal involvement Symptomatic neuropathy &gt; grade1 accord NCI CTCAE ( version 3.0 ) Cardiovascular disease ( class IIIV NYHA congestive heart failure , myocardial infarction within previous 4 month , LVEF &lt; normal , uncontrolled hypertension , ventricular arrhythmia ) , anticoagulation treatment thrombotic event within previous 6 month Active infection , require IV antibiotic treatment , within previous 2 week Longterm oxygen therapy Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Radiotherapy within previous 4 week Previous radiotherapy measurable lesion Concurrent treatment anticancer drug Uncontrolled hypercalcemia Known allergy drug similar chemical structure study drug . Concurrent corticosteroid , except chronic therapy methylprednisolone ≤ 20 mgr daily ( equivalent ) one month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>VInorelbine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>